

Andreas Clemens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11853486/publications.pdf>

Version: 2024-02-01

34
papers

4,402
citations

236833

25
h-index

360920

35
g-index

35
all docs

35
docs citations

35
times ranked

4658
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1116-1127.	1.8	1,330
2	Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 968-977.	1.8	320
3	Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 9S-16S.	0.7	289
4	Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. <i>Thrombosis Research</i> , 2009, 124, 37-41.	0.8	263
5	Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. <i>Thrombosis and Haemostasis</i> , 2012, 107, 838-847.	1.8	201
6	Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1885-1889.	1.1	198
7	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETWORK/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012, 14, 8-27.	0.7	193
8	Effective elimination of dabigatran by haemodialysis. <i>Thrombosis and Haemostasis</i> , 2013, 109, 596-605.	1.8	184
9	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2016, 134, 589-598.	1.6	140
10	Prognostic value of codon 918 (ATG?ACG)RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. <i>International Journal of Cancer</i> , 2001, 95, 62-66.	2.3	127
11	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETWORK/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013, 15, 1540-1556.	0.7	125
12	Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999, 435, 461-468.	1.4	116
13	Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>American Heart Journal</i> , 2014, 167, 329-334.	1.2	112
14	Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1106-1115.	1.8	98
15	Patient outcomes using the European label for dabigatran. <i>Thrombosis and Haemostasis</i> , 2014, 112, 933-942.	1.8	94
16	Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1373-1378.	1.0	78
17	Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran. <i>American Journal of Medicine</i> , 2012, 125, 417-420.	0.6	73
18	The Discovery of Dabigatran Etexilate. <i>Frontiers in Pharmacology</i> , 2013, 4, 12.	1.6	52

#	ARTICLE	IF	CITATIONS
19	Anticoagulant-related gastrointestinal bleeding“ could this facilitate early detection of benign or malignant gastrointestinal lesions?. <i>Annals of Medicine</i> , 2014, 46, 672-678.	1.5	51
20	Reversal of Dabigatran-induced Bleeding by Coagulation Factor Concentrates in a Rat-tail Bleeding Model and Lack of Effect on Assays of Coagulation. <i>Anesthesiology</i> , 2014, 120, 1429-1440.	1.3	50
21	Adsorption of Dabigatran Etxilate in Water or Dabigatran in Pooled Human Plasma by Activated Charcoal in Vitro.. <i>Blood</i> , 2009, 114, 1065-1065.	0.6	48
22	Pharmacometric Characterization of Dabigatran Hemodialysis. <i>Clinical Pharmacokinetics</i> , 2013, 52, 453-462.	1.6	40
23	Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. <i>PLoS ONE</i> , 2014, 9, e99276.	1.1	33
24	Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. <i>Vascular Health and Risk Management</i> , 2013, 9, 599.	1.0	30
25	The Successful Reversal of Dabigatran-Induced Bleeding by Coagulation Factor Concentrates in a Rat Tail Bleeding Model Do Not Correlate with Ex Vivo Markers of Anticoagulation. <i>Blood</i> , 2011, 118, 2316-2316.	0.6	27
26	Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2442-2444.	1.2	25
27	Critical Appraisal of Network Meta-Analyses Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials. <i>Value in Health</i> , 2015, 18, 234-249.	0.1	24
28	Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 607-616.	0.8	23
29	Efficacy and Cost-Effectiveness of Dabigatran Etxilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups. <i>American Journal of Cardiology</i> , 2014, 114, 849-855.	0.7	17
30	Quality of INR Control and Outcomes Following Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 370-378.	0.7	16
31	Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. <i>Thrombosis and Haemostasis</i> , 2016, 115, 562-569.	1.8	9
32	Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis“ A simulation analysis. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 597-608.	1.0	7
33	Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. <i>Thrombosis Research</i> , 2016, 143, 103-110.	0.8	4
34	Dabigatran Etxilate : Pharmacology of the New, Oral Direct Thrombin Inhibitor. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2011, 22, 143-150.	0.1	1